Glenmark Pharmaceuticals Overview
- Year Founded
-
1977
- Status
-
Public
- Employees
-
16,946
- Stock Symbol
-
532296
- Investments
-
11
- Share Price
-
$28.11
- (As of Friday Closing)
Glenmark Pharmaceuticals General Information
Description
Glenmark Pharmaceuticals Ltd is a specialty and generic drug manufacturing company. The company's research and development activity is focused on generating intellectual property assets that will help address unmet medical needs. Glenmark's product categories include novel molecular entities, formulations, and API products. The company considers merger and acquisition investment to be a potential component for expanding its research, development, manufacturing, and marketing capabilities. It has a business presence in different therapeutic areas such as dermatology, respiratory, oncology, diabetes, cardiovascular, and oral contraceptives among others. Geographically, it derives key revenue from India and the rest from North America, Latin America, Europe and the Rest of the world.
Contact Information
Website
www.glenmarkpharma.comCorporate Office
- Glenmark House, B. D. Sawant Marg
- Chakala, Off Western Express Highway, Andheri East
- Mumbai, 400099
- India
Corporate Office
- Glenmark House, B. D. Sawant Marg
- Chakala, Off Western Express Highway, Andheri East
- Mumbai, 400099
- India
Glenmark Pharmaceuticals Stock Performance
As of 13-Nov-2026, Glenmark Pharmaceuticals’s stock price is $28.11. Its current market cap is $7.93B with 282M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $28.11 | $28.34 | $20.10 - $28.89 | $7.93B | 282M | 24.5K | $0.55 |
Glenmark Pharmaceuticals Financials Summary
As of 30-Sep-2026, Glenmark Pharmaceuticals has a trailing 12-month revenue of $1.7B.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2026 31-Mar-2026 | FY 2025 31-Mar-2025 | FY 2024 31-Mar-2024 |
|---|---|---|---|---|
| EV | 6,723,856 | 6,168,611 | 5,040,921 | 3,749,733 |
| Revenue | 1,697,289 | 1,891,206 | 1,554,667 | 1,405,489 |
| EBITDA | 297,802 | 308,455 | 242,244 | 142,186 |
| Net Income | 156,530 | 154,119 | 123,833 | (181,392) |
| Total Assets | 2,228,006 | 2,109,945 | 1,876,278 | 1,721,792 |
| Total Debt | 146,533 | 62,905 | 289,068 | 147,605 |
Glenmark Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Glenmark Pharmaceuticals Comparisons
Industry
Financing
Details
Glenmark Pharmaceuticals Competitors (50)
One of Glenmark Pharmaceuticals’s 50 competitors is Strides Pharma Science, a Formerly VC-backed company based in Bangalore, India.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Strides Pharma Science | Formerly VC-backed | Bangalore, India | ||||
| Mankind Pharma | Formerly PE-Backed | New Delhi, India | ||||
| Evonile Pharma | Private Equity-Backed | Mumbai, India | ||||
| Jubilant Pharmova | Corporation | Noida, India | ||||
| Zydus Lifesciences | Corporation | Ahmedabad, India |
Glenmark Pharmaceuticals Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Glenmark Pharmaceuticals Patents
Glenmark Pharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026062552-A1 | Nebulization composition comprising glycopyrrolate, formoterol and budesonide | Pending | 19-Sep-2024 | ||
| US-12502489-B1 | Metered dose inhaler for ipratropium bromide solution | Active | 14-Sep-2024 | ||
| US-20260077140-A1 | Metered dose inhaler for ipratropium bromide solution | Pending | 14-Sep-2024 | ||
| EP-4731184-A1 | A pressurized inhalation composition of tiotropium | Pending | 26-Aug-2024 | ||
| WO-2025088589-A1 | Topical foam composition of roflumilast | Inactive | 27-Oct-2023 | A61P17/00 |
Glenmark Pharmaceuticals Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Glenmark Pharmaceuticals Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Glenmark Pharmaceuticals Investments & Acquisitions (11)
Glenmark Pharmaceuticals’s most recent deal was a Corporate with O2 Renewable Energy XXIV. The deal was made on 10-May-2024.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| O2 Renewable Energy XXIV | 10-May-2024 | Corporate | Alternative Energy Equipment | ||
| Sintesy | 26-Apr-2023 | Merger/Acquisition | Other Devices and Supplies | ||
| Wockhardt (OTC drugs) | 28-Jun-2022 | Corporate Asset Purchase | Buildings and Property | ||
| IndoHealth Services | 30-Apr-2021 | Corporate | Other Healthcare Services | ||
| Zorg Laboratories | 16-Jul-2018 | Merger/Acquisition | Distributors (Healthcare) |
Glenmark Pharmaceuticals ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
25.69 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,585
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Pharmaceuticals
Subindustry
of 354
Rank
Percentile
Glenmark Pharmaceuticals Exits (1)
Glenmark Pharmaceuticals’s most recent exit was on 22-Dec-2005 from Napo Pharmaceuticals. The exit was categorized as with 4 buyers.
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Napo Pharmaceuticals | 22-Dec-2005 | Completed |
|
Glenmark Pharmaceuticals Affiliates
Subsidiaries (2)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Sintesy | Milan, Italy | 1997 | |
| Marksans Pharma | Mumbai, India | 1992 |
Glenmark Pharmaceuticals FAQs
-
When was Glenmark Pharmaceuticals founded?
Glenmark Pharmaceuticals was founded in 1977.
-
Where is Glenmark Pharmaceuticals headquartered?
Glenmark Pharmaceuticals is headquartered in Mumbai, India.
-
What is the size of Glenmark Pharmaceuticals?
Glenmark Pharmaceuticals has 16,946 total employees.
-
What industry is Glenmark Pharmaceuticals in?
Glenmark Pharmaceuticals’s primary industry is Pharmaceuticals.
-
Is Glenmark Pharmaceuticals a private or public company?
Glenmark Pharmaceuticals is a Public company.
-
What is Glenmark Pharmaceuticals’s stock symbol?
The ticker symbol for Glenmark Pharmaceuticals is 532296.
-
What is the current stock price of Glenmark Pharmaceuticals?
As of 13-Nov-2026 the stock price of Glenmark Pharmaceuticals is $28.11.
-
What is the current market cap of Glenmark Pharmaceuticals?
The current market capitalization of Glenmark Pharmaceuticals is $7.93B.
-
What is Glenmark Pharmaceuticals’s current revenue?
The trailing twelve month revenue for Glenmark Pharmaceuticals is $1.7B.
-
Who are Glenmark Pharmaceuticals’s competitors?
Strides Pharma Science, Mankind Pharma, Evonile Pharma, Jubilant Pharmova, and Zydus Lifesciences are some of the 50 competitors of Glenmark Pharmaceuticals.
-
What is Glenmark Pharmaceuticals’s annual earnings per share (EPS)?
Glenmark Pharmaceuticals’s EPS for 12 months was $0.55.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
